Alzheimer's Disease

Author: Alene Burke RN, MSN
3 Contact Hours
Alene Burke & Associates is approved as a provider of Continuing Education by the Florida Board of Nursing, Provider # 50-2502


To take the test:
If you are not registered:

DESCRIPTION:

Alzheimer's disease is a widespread and commonly occurring form of senile dementia, predominately found in older adults although it is occasionally diagnosed among middle-aged adults.

It is a progressive, irreversible neurological disorder that is marked with the loss of cognitive ability, disturbances of behavior and personality changes. Cognitive losses include declines in terms of language, thinking and decision-making.

This course provides the learner with information about the etiology, pathophysiology, signs and symptoms and the pharmacological and nonpharmacological treatment of Alzheimer's disease and its symptoms.

OBJECTIVES:

At the conclusion of this course, the learner will be able to:
  1. Detail the etiology, pathophysiology, signs and symptoms of Alzheimer's disease.
  2. Discuss how the diagnosis of Alzheimer's disease is made.
  3. Describe pharmacological and nonpharmacologic interventions relating to Alzheimer's disease.

INTRODUCTION

Alzheimer's disease is a widespread and commonly occurring form of senile dementia, predominately found in older adults although it is occasionally diagnosed among middle-aged adults.

It is a progressive, irreversible neurological disorder that is marked with the loss of cognitive ability, disturbances of behavior and personality changes. Cognitive losses include declines in terms of language, thinking and decision-making.

Alzheimer's disease, first recognized in 1907 by German neurologist Alois Alzheimer, is not a function of the normal aging process.

INCIDENCE

Although the course of the disease varies among people, it is found that, on an average, a person will about 8 to 10 years after diagnosis, although some may live as long as 20 years after diagnosis. The symptoms generally begin to appear after 60 years of age with increasingly greater risk for onset, as the person grows older. The risk of the disease doubles for every 5-year increment after 65. The group at greatest risk is those 85 years of age and older. Some believe that almost half of those 85 years of age, and older, have dementia. About 3 percent of men and women ages 65 to 74 are affected by it.

At the current time, it is estimated that 4.5 million people have it. It is also estimated that, by the year 2050, 13.2 million people in our nation will have Alzheimer's disease should the increases in life expectancy materialize as it is expected to do.

At the current time, the direct and indirect costs of caring for people with Alzheimer's disease is about $100 billion a year in our country. Society and families are also affected with this disorder. About half of all Alzheimer's are cared for in their own home. Caregiving family members experience physical, emotional and financial stress as they care for the person in the home. (United States NIA & NIH, 2003)

Alzheimer's disease consists of two types. They are: The familial type of the disease accounts for about 75% of cases while the sporadic type accounts for the remaining 25% of the diagnosed cases. The familial type of Alzheimer's disease usually occurs at an earlier age than the sporadic type, typically before the age of 60. The sporadic type typically presents in later years.

ETIOLOGY

In recent years medical researchers have conducted numerous intensive studies to determine what factor or factors cause this severely devastating and widespread neurological disorder. Although no conclusive evidence has been produced as a result of these research efforts, some factors have been identified as plausible and possible causative agents of Alzheimers.

The cause of late onset Alzheimer's disease is not fully understood, however, it is known that about half of children with an affected parent may develop early onset Alzheimer's when they are as young as 30, 40 or 50. These people have a mutation in one of the following genes which are associated with an excess beta-amyloid: It appears that beta-amyloid is toxic and when beta-amyloid plaques from in the brain, the damage to brain function occurs. The key to a cure, therefore, may lie in our ability to speed up beta-amyloid removal or to slow down its production. (United States NIA & NIH, 2003)

The genetic model.

Some evidence supports the fact that heredity plays a role in the development of Alzheimer's disease, particularly among individuals diagnosed at an early age. Studies have indicated that if a parent or sibling has or has had the disease there is a greater risk of developing the disease. However, having an affected sibling or parent does not necessarily mean that one will develop Alzheimer's with 100% certainty.

Families with several victims of this disease have been studied and it has been found that some members of the family may get it and others do not. It appears that although genetics and heredity may play a role in the development of Alzheimer's disease, it may involve more than heredity alone.

The toxin model.

Other researchers have explored the role of aluminum in the development of Alzheimer's disease. Investigations into the role of aluminum from environmental sources such as drinking water, cooking pans and pots, antiperspirants and antacids as a causative or contributory agent have not led to the gathering of conclusive evidence in support of this theory.

THE WARNING SIGNS OF ALZHEIMER'S DISEASE

According to the National Institute on Aging, there are seven warning signs associated with Alzheimer's disease. They are as follows:
  1. "Asking the same question over and over again.
  2. Repeating the same story, word for word, again and again.
  3. Forgetting how to cook, or how to make repairs, or how to play cards - activities that were previously done with ease and regularity.
  4. Losing one's ability to pay bills or balance one's checkbook.
  5. Getting lost in familiar surroundings, or misplacing household objects.
  6. Neglecting to bathe, or wearing the same clothes over and over again, while insisting that they have taken a bath or that their clothes are still clean.
  7. Relying on someone else, such as a spouse, to make decisions or answer questions they previously would have handled themselves. (National Institute on Aging, 2005)

THE SIGNS AND SYMPTOMS OF ALZHEIMER'S DISEASE

The symptoms of Alzheimer's disease are often gradual and they may go unnoticed for many years. The first symptoms of Alzheimer's are forgetfulness and memory loss. The memory loss and forgetfulness is most often associated with recent events and novel information, rather than long-term memory. The affected individual may demonstrate a repetition of ideas in conversions or forget where they have left an object.

The person suffering from Alzheimer's may be unaware of any cognitive changes and often it is a family member, rather than the affected individual, who seeks medical help for the condition. As the disorder continues to progress, severe confusion and disorientation as well as personality and behavioral changes occur. A person may present with agitation, wandering, paranoia, depression, poor judgment, a lack of common or an inability to verbally express complex thoughts. They may no longer be able to perform simple activities of daily living like dressing, grooming, reading and writing.

Other treatable medical conditions, such as dehydration, malnutrition and a fever, mimic the symptoms of Alzheimer's disease so these conditions should be diagnosed and treated prior to a diagnosis of Alzheimer's disease.

The Alzheimer's Association lists the following signs of the early stage of the disease:

Recent memory loss that affects job skills.

It is normal to occasionally forget assignments, names, or telephone numbers and then remember them later. Those with a dementia, such as Alzheimer's disease, forget things with greater frequency and often fail to remember them even when reminded.

Difficulty performing familiar tasks.

Busy people can be so distracted from time to time that they may leave the carrots on the stove and only remember to serve them at the end of the meal. People with Alzheimer's disease may have difficulty going through the proper steps to prepare the carrots.

Problems with language.

Everyone has trouble finding the right words sometimes, but people with Alzheimer's disease forget simple words or substitute inappropriate words, making their sentences difficult to understand.

Disorientation to time and place.

It is normal to occasionally forget the day of the week or how to get where you are going. However, people with Alzheimer's disease may become lost in familiar surroundings, not knowing where they are, how they got there, or how to get back home.

Poor or decreased judgment.

People can become so immersed in an activity that they temporarily forget about something else that they are supposed to be doing at the same time, such as watching a child. People with Alzheimer's disease may entirely forget about the child under their care. They may also dress inappropriately for the weather or put on several shirts or blouses.

Problems with abstract thinking.

Balancing a checkbook may be disconcerting when the task is more complicated than usual. Someone with Alzheimer's disease may completely forget what the numbers are and what needs to be done with them.

Misplacing things.

Anyone can temporarily misplace a wallet or keys. A person with Alzheimer's disease may put things in inappropriate places. For example, they may place a carton of ice cream in a kitchen cabinet or they may put the milk in the freezer.

Changes in mood and behavior.

Everyone becomes sad or moody from time to time. Someone with Alzheimer's disease can exhibit rapid mood swings - from calm to tears to anger, for no apparent reason.

Changes in personality.

Personalities may change slightly with age. However, a person with Alzheimer's disease can change drastically, becoming extremely confused, suspicious, or fearful.

Loss of initiative.

It is normal to tire of housework, business activities, or social obligations, but most people regain their initiative. People with Alzheimer's disease may become very passive and require cues and prompting to become involved. (Alzheimer's Association, 2005)

Although the signs and symptoms of Alzheimer's disease can vary, the early signs and symptoms of the disease usually progress from short-term memory loss and personality changes to more severe degrees of debilitation. Those affected may demonstrate a diminishing ability to perform activities of daily living. They may have progressive loss of decision-making powers and display poor judgment. Aphasia, hostility, emotional instability, depression and agitation are also frequently seen.

Early Stage (Mild Form) Signs and Symptoms

The person: During the intermediate stage of Alzheimer's disease, long-term memory may become affected in addition to the already present short-term memory loss. The individual affected with Alzheimer's disease may become progressively more socially isolated and incapable of performing even the most basic activities such as bathing, cleaning the home and safely cooking their meals. They may become increasingly more disoriented and perhaps even have a tendency to wander and get lost.

Psychological and behavioral symptoms that began to appear in the early stages of the disease may progress, causing the individual to become severely aggressive, agitated and hostile. At this point, the safety and physical well being of the person as well as their quality of life becomes progressively more jeopardized as the disease continues on its course.

Intermediate Stage (Moderate Form) Signs and Symptoms In its most severe form, Alzheimer's disease may completely limit the ability of the individual to remain independent and perform some self-care activities. They may be unable to perform even simple activities of daily living, including ambulation. Severe psychosis with delusions, hallucinations and paranoia has been found to occur in about 10% of those affected with Alzheimer's disease. Safety continues to be a major concern. During the terminal phase of Alzheimer's disease long term and short term memory may be completely absent. Patients may have difficulty eating and swallowing, thus placing them at risk for malnutrition, dehydration and aspiration.

Additional challenges face those who provide care to this patient population in terms of assessment skills. Alzheimer's patients are often unable to communicate symptoms of illness so it is important to continuously assess and monitor these patients for the signs and symptoms of infection and disease. Typically, the end stage of Alzheimer's disease results from an infection that eventually leads to coma and death. Late Stage (Severe Form) Signs and Symptoms

PATHOPHYSIOLOGY

It is now believed that Alzheimer's disease is associated with a loss of cells in the hippocampus, cerebral cortex and the subcortical sections of the cerebrum and with cells in the locus ceruleus and nucleus raphis dorsalis in the brainstem. These are the areas of the brain associated with memory, cognition and thought processes. It is also believed that those with Alzheimer's disease may have less than normal cerebral glucose use. It is not clear whether this reduction follows or precedes the cellular destruction within the brain.

Although consensus among the members of the scientific community has not yet been reached, some researchers believe that beta-amyloid deposits may cause the cognitive deterioration seen in Alzheimer's. Amyloid is a starchlike protein that forms within and adjacent to the blood vessels in the affected areas of the brain. Amyloid protein deposits are notable for their staining properties and are composed of filaments or fibrils arranged in a twisted beta-pleated conformation. It is not known whether the presence of amyloid deposits in the brain is a primary cause of Alzheimer's or simply a feature of the disease.

Researchers have also explored the presence and frequency of neurofibrillary tangles and senile plaques among those with and without Alzheimer's disease. Neurofibrillary tangles are bundles of fibrous proteins found in the nerve cell bodies in the hippocampus, cerebral cortex and in the areas of the brainstem involved with the release of certain neurotransmitters.

Senile plaques are scattered bits of cellular debris, degenerating nerve terminals, amyloid deposits and glial cells that are associated with inflammatory reactions. These plaques tend to be localized in the area of the axons and dendrites rather than within the nerve cell bodies.

It has been found that neurofibrillary tangles and senile plaques, commonly seen phenomena associated with the normal aging process, appear to be more numerous and frequent in those persons diagnosed with Alzheimer's. These plaques and tangles play a role in the progressive pathology of the disease.

Protein abnormalities have also been found in patients with Alzheimer's disease. In addition, a reduction of choline acetyltransferase, somatostatin, corticotropin-releasing factor and several neurotransmitters has also been documented. Although the normal aging process is associated with some decreased neurotransmission, the multiple neurotransmission defects seen in patients with Alzheimer's are far greater and more severe.

Recent research indicates that apolipoprotein E2 (apoE2), previously known for its biochemical role in cholesterol transport, may serve as a protective mechanism against the disease. A variant, apoE4 may indicate susceptibility because apoE4 attaches to beta-amyloid, a protein associated with the development and onset of the disease. (Beers & Berkow, 2005)

DIAGNOSIS

The diagnosis of Alzheimer's disease is complex and challenging, particularly in its early stages. It is difficult to differentiate normal forgetfulness and a slowed rate of learning from pathological cognitive deficits associated with the disease itself.

Diagnosis involves a synthesis of information from a complete medical history and physical examination, laboratory tests, brain scans, neuropsychological tests that measure problem solving skills, counting, language and memory.

The only definitive diagnosis for Alzheimer's disease is a post-mortem brain tissue biopsy, which reveals the plaques and tangled brain tissue characteristic of Alzheimer's disease. Any diagnosis of Alzheimer's disease is a probable or possible one until the person is dead. Before a probable diagnosis is made, however, other possibilities such as thyroid disease, an untoward side effect of a medication, depression, brain tumors and other medical conditions must be ruled out.

The following diagnostic criteria developed by the Alzheimer's Association helps to facilitate early and accurate diagnosis. Before these strict diagnostic criteria were imposed, Alzheimer's disease was misdiagnosed up to 50% of the time. Now, it is accurately diagnosed by specialists up to 90% of the time.
  1. Dementia established by clinical examination; documented by the Mini-Mental State Examination, Blessed Dementia Scale, or a similar examination; and confirmed by neuropsychologic tests.
  2. Deficits in two or more areas of cognition.
  3. Progressive worsening of memory and other cognitive functions.
  4. No disturbance of consciousness.
  5. Onset between the ages of 40 and 90 years, most often after age 65.
  6. No systemic disorders or brain diseases that could account for the progressive deficits in memory and cognition. (Alzheimer's Association, 2005)
Until a definitive test is available, a number of other diagnostic tests can be performed to rule out other causes of the dementia. Some of the tests include electrolyte levels, CBC (complete blood count), folate and B12 levels, thyroid function tests, urinalysis, VDRL (Venereal Disease Research Laboratories) and an EKG. An MRI or CT is also done when a brain mass, infarct or hematoma is suspected. After the testing and assessment has eliminated all other causes of the dementia, a diagnosis of Alzheimer's disease is generally made.

A current research goal is the development of a noninvasive and accurate test for the disease. This test may involve the identification of some biological markers, such as a specific kind of protein, or a more advanced form of medical imaging than is now available.

THE PHARMACOLOGICAL TREATMENT OF ALZHEIMER'S DISEASE

As stated previously, there is no cure for Alzheimer's disease. It is unrelenting and progressive. There are, however, some medications that can prevent the symptoms from worsening, at least for a period of time. These medications include: Other medications are used to help control some of the disturbing behavioral changes relating to the disease, such as depression, agitation, wandering and anxiety. The goals of this therapy is to make the lives of the affected individual and their caregivers less problematic and more comfortable, whenever possible. CNS depressants, antidepressants and antipsychotic medication, however, can produce greater lethargy and confusion so caution and monitoring is necessary.

Tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon) and galantamine (Razadyne) are cholinesterase inhibitors. It appears that this classification of medication may prevent the breakdown of acetylcholine until the Alzheimer's disease progresses to a point when acetylcholine is only minimally produced by the brain, thus rendering the medication less useful or useless. Acetylcholine chemically enhances memory and other cognitive processes.

Tacrine

Tacrine (Cognex) improves cholinergic neurotransmission and provides some improvement for patients with mild to moderate dementia. Tacrine inhibits the enzyme cholinesterase, an enzyme responsible for the breakdown of acetylcholine in the synapse of nerve cells. Tacrine allows acetylcholine to remain in the synapse thereby temporarily improving cognitive function.

The initial dosage is 10 mg four times a day and can be increased up to 40 mg four times a day until the desired effects are achieved. Tacrine should be discontinued with those patients who develop jaundice. Since the medication may increase transaminase levels, caution should be exercised when administering Tacrine to patients with a history of abnormal liver function tests. Once the patient is on Tacrine therapy it is necessary to monitor liver function.

Other adverse effects to tacrine (Cognex) include bradycardia, peptic ulcer, ataxia, nausea, vomiting, diarrhea, anorexia, dyspepsia and myalgia. Toxicity is marked with a severe cholinergic crisis accompanied by severe salivation, sweating, bradycardia, nausea, vomiting, hypotension, convulsion and muscular weakness. In its most severe form toxicity could lead to respiratory arrest.

The recommended antidote is a titrated solution of IV atropine sulfate until the desired reversal of toxic symptoms has been achieved. It is recommended that Tacrin be taken between meals since its absorption is inhibited by the presence of food in the stomach.

Donepezil

Donepezil (Aricept) acts in the same manner as Cognex. The initial dosage is 5 mg per day at bedtime. The dosage can be increased to 10 mg a day after 4 to 6 weeks of treatment that has not achieved its therapeutic effect.

Some of the side effects of this medication include: This medication is contraindicated with hypersensitivity and it must be used cautiously if the patient has a history of asthma, COPD, cardiovascular disease and/ulcers.

Rivastigmine

Rivastigmine (Exelon), another cholinesterase inhibitor, should be used cautiously with asthma, GI and urinary obstructions, cardiovascular disease, hypotension, a history of ulcers, seizures, epilepsy, uncontrolled diabetes and thyroid problems.

Typically, this medication is taken two times a day, best taken with meals and at regular times each day. The initial dosage is usually 1.5 mg twice a day. It can be increased up to 6 mg a day, as indicated. Rivastigmine toxicity can lead to convulsions, severe nausea and vomiting, muscular weakness, diaphoresis, excessive salivation, seizures and shock (large pupils, irregular breathing, dramatic hypotension and a rapid weak pulse).

Some of the side effects of Rivastigmine (Exelon) include: Galantamine

The side effects of galantamine (Razadyne) include: Drinking six to eight glasses of water every day while taking galantamine can decrease the risk of GI side effects.

Memantine

Namenda (memantine) is quite different from the four above cholinesterase inhibitors. This medication is an N-methyl D-aspartate (NMDA) antagonist. This medication offers some patients the hope of being able to continue some activities of daily living for a longer period of time. For example, it may enable people to dress themselves for a longer period of time than they would have been able to without this medication.

It is believed that this medication regulates excessive levels of glutamate, a chemical that leads to cellular brain tissue death. The recommended therapeutic dosage of Namenda is 20 mg per day after lesser doses have been tolerated. A dosage of 5 mg a day is taken as a single dose; larger doses are taken divided q 12 hours. .

It can be taken with or without food, but it should be taken with at least one full glass of water. The patient should use caution with driving and the operation of machinery as well as other hazardous activities because this medication can cause dizziness, fainting and drowsiness,

Some of the side effects of Namenda (memantine) include:

CARING FOR THE PERSON WITH ALZHEIMER'S DISEASE

There is no cure for Alzheimer's disease. The disease is progressive with increasing levels of cognitive decline and debilitation. During the initial stages of the disease the affected individual should be encouraged to remain as active and self sufficient as possible. Modifying the environment for safety and security is advisable. The use of alarms and signals is advised for those who wander and get lost.

Other modifications include the elimination of clutter and help with activities of daily living when necessary. Additional treatments include individual and family counseling, orientation therapy, physical exercise to decrease restlessness, music therapy, occupational therapy, reminiscence and socialization groups.

Additionally, the health care team (nursing, home health, rehabilitation, physicians and dietitians, social workers and mental health counselors) should involve the patient's family and caregivers. Often they are in need of such things as assistance, guidance, support and education in order to cope with the physically and emotionally demanding aspects of this devastating disease. Respite care, day care and long term care facilities should be suggested when the need arises. Often a nursing home, especially one with a special unit for Alzheimer's residents, becomes a difficult but necessary decision for the family.

Generally speaking, people with Alzheimer's disease do better in a familiar environment with predictable routines. Below are some care guidelines that should be used by professional healthcare workers as well as caregivers in the home.

Bathing Mouth Care Dressing Eating Incontinence Wandering Sleep Problems Communication Repetitive Speech and Gestures Catastrophic Reactions Hiding Things Aggressive Behaviors Sundowning Inappropriate Sexual Behaviors Fear Shadowing Hallucinations and Delusions Profanity and Obscenity Activities Driving Handling Money and Valuables Holidays Visiting the Doctor/Dentist

ALZHEIMER'S RESOURCES

Alzheimer's Association
225 North Michigan Avenue Suite 1700
Chicago, IL 60601-7633
1-800-272-3900
Web address: www.alz.org
This nonprofit association supports families and caregivers of patients with AD. Almost 300 chapters nationwide provide referrals to local resources and services, and sponsor support groups and educational programs. Online and print versions of publications are also available at the web site.

Alzheimer's Disease Education and Referral (ADEAR) Center
PO Box 8250
Silver Spring, MD 20907-8250
1-800-438-4380 (voice) 301-495-3334 (fax)
Web address: www.alzheimers.org
This service of the National Institute on Aging is funded by the Federal Government. It offers information and publications on diagnosis, treatment, patient care, caregiver needs, long-term care, education and training, and research related to AD. Staff answer telephone and written requests and make referrals to local and national resources. Publications and videos can be ordered through the ADEAR Center or via the web site.

Children of Aging Parents P.O. Box 167 Richboro, PA 18954 1-800-227-7294
Web address: www.caps4caregivers.org
This nonprofit group provides information and materials for adult children caring for their older parents. Caregivers of people with Alzheimer's disease also may find this information helpful.

Eldercare Locator 1-800-677-1116
Web address: www.eldercare.gov
The Eldercare Locator is a nationwide, directory assistance service helping older people and their caregivers locate local support and resources for older Americans. It is funded by the Administration on Aging (AoA), which also provides a caregiver resource called Because We Care - A Guide for People Who Care. The AoA Alzheimer's Disease Resource Room contains information for families, caregivers, and professionals about AD, caregiving, working with and providing services to persons with AD, and where you can turn for support and assistance.

Family Caregiving Alliance
180 Montgomery Street Suite 1100
San Francisco, CA 94104
1-800-445-8106
Web address: www.caregiver.org
Family Caregiver Alliance is a community-based nonprofit organization offering support services for those caring for adults with AD, stroke, traumatic brain injuries and other cognitive disorders. Programs and services include an Information Clearinghouse for FCA's publications.

The National Institute on Aging Information Center
P.O. Box 8057
Gaithersburg, Maryland 20898-8057
1-800-222-2225 (voice) 1-800-222-4225 (TTY)
Web address: www.nia.nih.gov
The National Institute on Aging (NIA) offers a variety of information about health and aging, including the Age Page series and the NIA Exercise Kit, which contains an 80-page exercise guide and 48-minute closed-captioned video. Caregivers can find many Age Pages on the NIA Publications ordering website at www.niapublications.org. NIHSeniorHealth.gov is a senior-friendly website from NIA and the National Library of Medicine. Located at www.nihseniorhealth.gov, the website features popular health topics for older adults.

The Simon Foundation for Continence
P.O. Box 815
Wilmette, IL 60091
1-800-237-4666
Web address: www.simonfoundation.org The Simon Foundation for Continence helps individuals with incontinence, their families, and the health professionals who provide their care. The Foundation provides books, pamphlets, tapes, self-help groups, and other resources.

Well Spouse Foundation
63 West Main Street, Suite H
Freehold, NJ 07728
1-800-838-0879
Web address: www.wellspouse.org
Well Spouse is a nonprofit membership organization that gives support to wives, husbands, and partners of the chronically ill and/or disabled. Well Spouse publishes the bimonthly newsletter, Mainstay.

SUMMARY

Alzheimer's disease is a common progressive neurological disorder with a high incidence among the elderly. As Americans enjoy a longer life expectancy the incidence of Alzheimer's disease has increased. The symptoms of this complex disease and the impact on both the patient and the family requires that healthcare professionals understand the disease and the ways we can care for those affected by the disease.

REFERENCES

Alzheimer's Association (2005) Available from URL: www.alzheimers.org

Beers, Mark H. and Robert Berkow, Editors (2005). The Merck Manual of Diagnosis and Therapy. Cognitive Failure: Delirium and Dementia. Available from: URL: www.merck.com

Lippincott, Williams and Wilkins. (2001) The Lippincott Manual of Nursing Practice, Seventh Edition.

Mosby. (2001). Mosby's Nursing Drug Reference CD ROM.

National Institute on Aging. (2005). Alzheimer's Disease. Available from URL: www.alzheimers.org

National Institute on Aging. (2005). Tips for Caregivers of People with Alzheimer's Disease. Available from URL: www.alzheimers.org/careguide.htm

National Institute on Aging and the National Institute of Health. (2003). Alzheimer's Disease. Available from URL: www.alzheimers.org

Copyright © Alene Burke 2005.

Contact Hours: 3
Price: $20.00
Course Title: Alzheimer's Disease
Course Number: 20-73927

back to the top

To take the test:
If you are not registered: